StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Positive trial data showing noninferiority with simplified regimens and reduced bleeding supports higher adoption of WATCHMAN FLX Pro. If guideline updates or payer support follow, BSX could see accelerated device volumes and modest margin expansion, though lack of revenue detail and real-world adoption uncertainty remain risks.
What happened, with direct paths to the underlying reporting
Boston Scientific reported six-month SIMPLAAFY data for the WATCHMAN FLX Pro LAAC device in NVAF, showing aspirin alone or reduced-dose NOAC regimens noninferior to DAPT. The regimens yielded less bleeding, with reduced-dose NOAC showing the lowest device-related thrombus at 0.9% versus 3.4% for DAPT (P=0.01). These findings could simplify post-implant care and bolster WATCHMAN adoption, potentially supporting near-term device volumes.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.